DiaMedica Therapeutics Inc. Shareholders' Equity
DiaMedica Therapeutics Inc. (DMAC) had Shareholders' Equity of $38.34 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-10
- 2026-06-30: Stockholders' Equity Attributable to Parent $38.34M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $47.23M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $56.11M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $51.62M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $38.34M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $47.23M 10-Q · filed 2026-08-10 |
| 2025-12-31 | $56.11M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $51.62M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $27.17M 10-Q · filed 2026-08-10 |
| 2025-03-31 | $33.95M 10-Q · filed 2026-08-10 |
| 2024-12-31 | $40.72M 10-Q · filed 2026-08-10 |
| 2024-09-30 | $47.96M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $53.41M 10-Q · filed 2025-11-12 |
| 2024-03-31 | $46.35M 10-Q · filed 2025-11-12 |
| 2023-12-31 | $51.06M 10-K · filed 2026-03-30 |
| 2023-09-30 | $55.63M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $59.74M 10-Q · filed 2024-11-13 |
| 2023-03-31 | $27.02M 10-Q · filed 2024-11-13 |
| 2022-12-31 | $31.83M 10-K · filed 2025-03-17 |
| 2022-09-30 | $35.08M 10-Q · filed 2023-11-13 |
| 2022-06-30 | $37.72M 10-Q · filed 2023-11-13 |
| 2022-03-31 | $40.77M 10-Q · filed 2023-11-13 |
| 2021-12-31 | $44.02M 10-K · filed 2024-03-19 |
| 2021-09-30 | $47.04M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $20.32M 10-Q · filed 2022-11-09 |
| 2021-03-31 | $23.14M 10-Q · filed 2022-11-09 |
| 2020-12-31 | $26.01M 10-K · filed 2023-03-28 |
| 2020-09-30 | $29.76M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $11.27M 10-Q · filed 2021-11-10 |
| 2020-03-31 | $13.32M 10-Q · filed 2021-11-10 |
| 2019-12-31 | $7.62M 10-K · filed 2022-03-14 |
| 2019-09-30 | $9.70M 10-Q · filed 2020-11-04 |
| 2019-06-30 | $11.70M 10-Q · filed 2020-11-04 |
| 2019-03-31 | $13.91M 10-Q · filed 2020-11-04 |
| 2018-12-31 | $17.02M 10-K · filed 2021-03-10 |
| 2018-09-30 | $4.11M 10-Q · filed 2019-11-13 |
| 2018-06-30 | $5.36M 10-Q · filed 2019-08-13 |
| 2018-03-31 | $6.75M 10-Q · filed 2019-05-13 |
| 2017-12-31 | $799.00K 10-K · filed 2020-03-23 |
| 2016-12-31 | $1.11M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |